Platform & Pipeline

Pipeline

 

Cerulean's Dynamic Tumor Targeting™ Platform has generated a portfolio of NDCs with the goal of producing next-generation cancer therapies. Cerulean’s platform-generated lead NDC clinical candidate, CRLX101, is in multiple clinical trials. Cerulean's second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.